Clinical Trial Update: Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

View source ↗

Summary

A completed Korean trial evaluating the safety and efficacy of Relestat Ophthalmic Solution 0.05% for allergic conjunctivitis, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Relestat Ophthalmic Solution 0.05% (olopatadine hydrochloride)

Snippet

Sponsor: Allergan | Conditions: Conjunctivitis, Allergic | Status: COMPLETED | Results posted: 2014-04-29